Streetbeat News

Stock Prices

TRUP

Trupanion (NASDAQ:TRUP) is set to release its quarterly earnings report on August 3, 2023. Analysts estimate an EPS of $-0.41. The company's past performance shows a trend of missing EPS estimates, which has led to significant drops in share price. The stock is currently trading at $29.29, down 56.23% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 11:54 am

WAT

Waters Corporation reported better-than-expected Q2 results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 11:54 am

NCLH

Susquehanna analyst Christopher N. Stathoulopoulos downgraded Norwegian Cruise Line Holdings Ltd (NYSE:NCLH) to Neutral from Positive at a price target of $17 following Q2 FY23 results. Despite reporting strong Q2 sales growth and beating analyst consensus, the company's adjusted EBITDA is expected to take some time to return to pre-pandemic levels. Barclays also lowered the price target to $21 from $22, maintaining an Equal-Weight rating.

Portfolio Pulse from Lekha Gupta

August 04, 2023 | 11:54 am

BGNE

BeiGene's shares are trading lower after the company reported mixed Q2 results.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 11:54 am

CERE

Cerevel Therapeutics (NASDAQ:CERE) shares are trading lower after the company reported Q2 earnings and a pipeline update. The company has delayed data readout for Emraclidine, a drug in development for schizophrenia and Alzheimer's disease psychosis. The data from two schizophrenia trials is now expected in 2H of 2024, later than the earlier expectation of 1H 2024. The company has also initiated Phase 1 trials for emraclidine in elderly healthy volunteers and is conducting a Phase 2a exploratory trial in dementia-related apathy for CVL-871. The timeline for this trial is under review due to challenges in identifying the appropriate patient population.

Portfolio Pulse from Vandana Singh

August 04, 2023 | 11:54 am

BPMC

In the last quarter, 15 analysts have provided ratings for Blueprint Medicines (NASDAQ:BPMC), with 6 being bullish, 3 somewhat bullish, 5 indifferent, and 1 somewhat bearish. The company has an average 12-month price target of $69.6, which has increased by 20.37% over the past month.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 11:53 am

AXTA

Axalta Coating Sys (NYSE:AXTA) has received various analyst ratings in the last quarter, with 3 bullish, 1 somewhat bullish, 2 indifferent, and 1 somewhat bearish. Over the past 3 months, 7 analysts have offered 12-month price targets for Axalta, with an average price target of $35.0, a high of $38.00, and a low of $31.00. The average price target has increased by 7.69% over the past month.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 11:53 am

AAPL

GLD

GOOG

IWM

JPM

MSFT

QQQ

SPY

TLT

WFC

The article discusses potential strategies for traders to profit from the Fitch downgrade of US bonds, similar to the 2011 downgrade by Standard & Poor's. It suggests shorting SPY, QQQ, and IWM, buying puts, and trading volatility. It also mentions that stocks like AAPL, GOOG, JPM, WFC, and MSFT fell significantly after the 2011 downgrade. The article suggests that TLT, GLD, and VIX could be profitable trades in the current scenario.

Portfolio Pulse from Sandra Stone

August 04, 2023 | 11:53 am

PAYC

Paycom Software's shares are trading lower following the release of their Q2 results.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 11:53 am

HAS

Rapper Post Malone has reportedly purchased the rarest Magic: The Gathering card, owned by Hasbro Inc (NASDAQ:HAS), for $2.6 million. The card, part of the Lord of the Rings set launched in 2023, is a one-of-one card, meaning there is only one in existence. The purchase comes as Magic: The Gathering sees strong sales growth for Hasbro, with the company reporting a 16% YoY increase in segment revenue in Q1.

Portfolio Pulse from Chris Katje

August 04, 2023 | 11:53 am